Evidence map›Paper›PMID 38726920›Full record

Trial reportJournal of the American Heart Association2024

Prognostic Value and Determinants of High-Sensitivity Cardiac Troponin T in Patients With a Systemic Right Ventricle: Insights From the SERVE Trial.

Francisco Javier Ruperti-Repilado, Fabian Tran, Philip Haaf, Pedro Lopez-Ayala, Matthias Greutmann, Markus Schwerzmann, Judith Bouchardy, Harald Gabriel, Dominik Stambach, Tobias Rutz and 5 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03049540 (Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function - a Multi-center, Double-blind, Randomized, Placebo-controlled Clinical Trial - SERVE Trial), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03049540 phase3completednot on this map

Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function - a Multi-center, Double-blind, Randomized, Placebo-controlled Clinical Trial - SERVE Trial

TypeinterventionalSponsorInsel Gruppe AG, University Hospital BernRan2017 to 2021Enrolled100ConditionsHeart Defects, Congenital, Transposition of Great Vessels With Ventricular InversionArmsTadalafil 20 MG, Placebo 20 MG
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Francisco Javier Ruperti-RepiladoDivision of Cardiology University Hospital of Basel Basel Switzerland.ORCID 0000-0002-9904-0402
Fabian TranDivision of Cardiology Cardiovascular Research Institute Basel, University Hospital Basel, Switzerland Basel Switzerland.
Philip HaafDivision of Cardiology University Hospital of Basel Basel Switzerland.ORCID 0000-0002-5657-6637
Pedro Lopez-AyalaDivision of Cardiology Cardiovascular Research Institute Basel, University Hospital Basel, Switzerland Basel Switzerland.ORCID 0000-0002-7787-0640
Matthias GreutmannDepartment of Cardiology University Heart Center, University of Zurich Zurich Switzerland.ORCID 0000-0002-8692-6108
Markus SchwerzmannUniversity Clinic of Cardiology, Center for Congenital Heart Disease Inselspital, University Hospital Bern Switzerland.ORCID 0000-0002-4006-8929
Judith BouchardyDivision of Cardiology Lausanne University Hospital Lausanne Switzerland.ORCID 0000-0003-0149-288X
Harald GabrielDepartment of Cardiology Medical University of Vienna, Adult Congenital Heart Disease Program Vienna Austria.ORCID 0000-0002-2652-7092
Dominik StambachDepartment of Cardiology Kantonsspital St Gallen St Gallen Switzerland.
Tobias RutzUniversity Clinic of Cardiology, Center for Congenital Heart Disease Inselspital, University Hospital Bern Switzerland.ORCID 0000-0001-5899-291X
Juerg SchwitterDivision of Cardiology Lausanne University Hospital Lausanne Switzerland.ORCID 0000-0002-9966-6149
Kerstin WustmannDivision of Cardiology Lausanne University Hospital Lausanne Switzerland.ORCID 0000-0002-6890-0692
Michael FreeseDivision of Cardiology Cardiovascular Research Institute Basel, University Hospital Basel, Switzerland Basel Switzerland.
Christian MuellerDivision of Cardiology University Hospital of Basel Basel Switzerland.ORCID 0000-0002-1120-6405
Daniel ToblerDivision of Cardiology University Hospital of Basel Basel Switzerland.ORCID 0000-0002-0821-3196

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe determinants and prognostic value of high-sensitivity cardiac troponin T (hs-cTnT) among patients with a systemic right ventricle are largely unknown. METHODS AND

resultsNinety-eight patients from the randomized controlled SERVE (Effect of Phosphodiesterase-5 Inhibition With Tadalafil on Systemic Right Ventricular Size and Function) trial were included. The correlation between baseline hs-cTnT concentrations and biventricular volumes and function quantified by cardiac magnetic resonance or cardiac multirow detector computed tomography was assessed by adjusted linear regression models. The prognostic value of hs-cTnT was assessed by adjusted Cox proportional hazards models, survival analysis, and concordance statistics. The primary outcome was time to the composite of clinically relevant arrhythmia, hospitalization for heart failure, or all-cause death. Median age was 39 (interquartile range, 32-48) years, and 32% were women. Median hs-cTnT concentration was 7 (interquartile range, 4-11) ng/L. Coefficients of determination for the relationship between hs-cTnT concentrations and right ventricular end-systolic volume index and right ventricular ejection fraction (RVEF) were +0.368 (

conclusionsHs-cTnT concentration was significantly correlated with right ventricular ejection fraction and right ventricular end-systolic volume index in patients with a systemic right ventricle. The prognostic accuracy of hs-cTnT was comparable to that of right ventricular ejection fraction and peak oxygen uptake predicted. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03049540.

Indexed as

BiomarkersStroke VolumeTroponin TVentricular Dysfunction, RightVentricular Function, RightAdultFemaleHeart FailureHeart VentriclesHumansMaleMiddle AgedMultidetector Computed TomographyPhosphodiesterase 5 InhibitorsPredictive Value of TestsPrognosisBiomarkersPhosphodiesterase 5 InhibitorsTroponin Tadult congenital heart diseasehigh‐sensitivity cardiac troponin Trisk stratificationsystemic right ventricle

Identifiers

PMID38726920
PMCPMC11179810

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.